AstraZeneca, Jacobio Pharma Sign Global License Deal for Pan-KRAS Inhibitor

MT Newswires Live12-22 18:53

AstraZeneca (AZN) has signed a deal with Jacobio Pharma for the exclusive development and commercialization rights for its JAB-23E73 inhibitor outside of China, Jacobio said Sunday.

In China, the companies will jointly develop and commercialize JAB-23E73.

Under the terms of the deal, Jacobio will receive a $100 million upfront payment and is eligible for additional development and commercial milestone payments of as much as $1.92 billion, as well as tiered royalties on net sales achieved outside of China, it said.

JAB-23E73 is meant to help target multiple KRAS mutation subtypes. KRAS is the most frequently mutated oncogene in human cancers.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593464489?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-22 18:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593464489","market":"sh","top_or_hot":-1,"title":"AstraZeneca, Jacobio Pharma Sign Global License Deal for Pan-KRAS Inhibitor","media":"MT Newswires Live","content":"<html><body><p> AstraZeneca (AZN) has signed a deal with <a href=\"https://laohu8.com/S/01167\">Jacobio</a> Pharma for the exclusive development and commercialization rights for its JAB-23E73 inhibitor outside of China, Jacobio said Sunday.</p><p>In China, the companies will jointly develop and commercialize JAB-23E73.</p><p>Under the terms of the deal, Jacobio will receive a $100 million upfront payment and is eligible for additional development and commercial milestone payments of as much as $1.92 billion, as well as tiered royalties on net sales achieved outside of China, it said.</p><p>JAB-23E73 is meant to help target multiple KRAS mutation subtypes. KRAS is the most frequently mutated oncogene in human cancers.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca, Jacobio Pharma Sign Global License Deal for Pan-KRAS Inhibitor</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca, Jacobio Pharma Sign Global License Deal for Pan-KRAS Inhibitor\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-22 18:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AstraZeneca (AZN) has signed a deal with <a href=\"https://laohu8.com/S/01167\">Jacobio</a> Pharma for the exclusive development and commercialization rights for its JAB-23E73 inhibitor outside of China, Jacobio said Sunday.</p><p>In China, the companies will jointly develop and commercialize JAB-23E73.</p><p>Under the terms of the deal, Jacobio will receive a $100 million upfront payment and is eligible for additional development and commercial milestone payments of as much as $1.92 billion, as well as tiered royalties on net sales achieved outside of China, it said.</p><p>JAB-23E73 is meant to help target multiple KRAS mutation subtypes. KRAS is the most frequently mutated oncogene in human cancers.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0889565916.HKD","symbol_name":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2593464489","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593464489","pubTimestamp":1766400823,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AstraZeneca  has signed a deal with Jacobio Pharma for the exclusive development and commercialization rights for its JAB-23E73 inhibitor outside of China, Jacobio said Sunday.In China, the companies will jointly develop and commercialize JAB-23E73.Under the terms of the deal, Jacobio will receive a $100 million upfront payment and is eligible for additional development and commercial milestone payments of as much as $1.92 billion, as well as tiered royalties on net sales achieved outside of China, it said.JAB-23E73 is meant to help target multiple KRAS mutation subtypes. KRAS is the most frequently mutated oncogene in human cancers.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","AZN":"阿斯利康","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4007":"制药","BK4588":"碎股","BK4568":"美国抗疫概念","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4585":"ETF&股票定投概念","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC"},"translate_title":"阿斯利康与Jacobio Pharma签署泛KRAS抑制剂全球许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"AstraZeneca (AZN) has signed a deal with Jacobio Pharma for the exclusive development and commercialization rights for its JAB-23E73 inhibitor outside of China, Jacobio said Sunday.In China, the companies will jointly develop and commercialize JAB-23E73.Under the terms of the deal, Jacobio will receive a $100 million upfront payment and is eligible for additional development and commercial milestone payments of as much as $1.92 billion, as well as tiered royalties on net sales achieved outside of China, it said.JAB-23E73 is meant to help target multiple KRAS mutation subtypes. KRAS is the most frequently mutated oncogene in human cancers.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593464489","isCrawlerRequest":true}